» Articles » PMID: 38476794

Prevalence and Comorbidities Among Individuals With Rheumatoid Arthritis in the Saudi Arabian Context

Abstract

Background:  Rheumatoid arthritis (RA) in Saudi Arabia (SA) is a significant health concern with a notable impact on individuals and the healthcare system. This study aimed to investigate the prevalence and profile of comorbidities in patients with RA.

Methodology:  This is a retrospective descriptive study involving 150 RA patients from August 2022 to August 2023, which was conducted at Khamis Mushait General Hospital, a major healthcare institution in SA. We examined the medical records to gather pertinent information. Stata Statistical Software: Release 18 (2023; StataCorp LLC, College Station, Texas, United States) was used for data analysis. The examination focused on sociodemographic factors, disease duration, prescribed medications (including methotrexate and biologic therapy), and the presence of comorbidities. Approval for the study was obtained from the Institutional Review Board of the Aseer Ministry of Health (approval number: H-06-B-091).

Results:  The study found a high prevalence of comorbidities in patients with RA. Around 96.7% of the patients had at least one documented comorbidity, highlighting this population's burden of additional health conditions. The most common comorbidity observed was anemia, affecting 48.7% of the patients. Other frequently observed comorbidities include hypertension, hyperlipidemia, diabetes mellitus, osteoporosis, interstitial lung disease, chronic renal disease, stroke, and coronary artery disease. The factors influencing comorbidities included an odds ratio of 1.086 (p=0.025), while being male was associated with lower odds (odds ratio=0.529, p=0.017). Additionally, disease duration (odds ratio=1.164, p=0.007), methotrexate use (odds ratio=2.553, p=0.001), and receiving biologic therapy (odds ratio=3.488, p<0.001) were significant contributors to comorbidities.

Conclusion:  These findings highlight the need for comprehensive approaches to address RA and its associated comorbidities. Research and awareness initiatives are essential to understand better the specific nuances of RA in SA, leading to improved diagnostic and treatment strategies for the needs of the local population.

Citing Articles

Rheumatoid arthritis and COVID-19 outcomes: a systematic review and Meta-analysis.

Jin L, Gan J, Li X, Lu Y, Wang Y, Wong V BMC Rheumatol. 2024; 8(1):61.

PMID: 39529202 PMC: 11555839. DOI: 10.1186/s41927-024-00431-5.

References
1.
Almalag H, Almaghlouth I, Dabbagh R, Alsalem A, Alrajban F, Algarni S . Prevalence of fatigue functional and social impairment among patients with rheumatic diseases compared to patients without: A cross-sectional comparison. Medicine (Baltimore). 2023; 102(9):e33151. PMC: 9981388. DOI: 10.1097/MD.0000000000033151. View

2.
Cici D, Corrado A, Rotondo C, Cantatore F . Wnt Signaling and Biological Therapy in Rheumatoid Arthritis and Spondyloarthritis. Int J Mol Sci. 2019; 20(22). PMC: 6888549. DOI: 10.3390/ijms20225552. View

3.
Frazzei G, van Vollenhoven R, de Jong B, Siegelaar S, van Schaardenburg D . Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes. Front Immunol. 2022; 13:899372. PMC: 9281565. DOI: 10.3389/fimmu.2022.899372. View

4.
Rivellese F, Surace A, Goldmann K, Sciacca E, Cubuk C, Giorli G . Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nat Med. 2022; 28(6):1256-1268. PMC: 9205785. DOI: 10.1038/s41591-022-01789-0. View

5.
Bucholc M, Bradley D, Bennett D, Patterson L, Spiers R, Gibson D . Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19. Sci Rep. 2022; 12(1):17313. PMC: 9568958. DOI: 10.1038/s41598-022-20176-w. View